These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37792377)

  • 1. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
    Mateo-Urdiales A; Sacco C; Petrone D; Bella A; Riccardo F; Del Manso M; Bressi M; Siddu A; Brusaferro S; Palamara AT; Rezza G; Pezzotti P; Fabiani M;
    JAMA Netw Open; 2023 Oct; 6(10):e2336854. PubMed ID: 37792377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
    Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
    JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
    Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
    Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
    Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC
    J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Kim HK; Park SK; Choe SA; Gwak ES; Cowling BJ; Kim YM; Lee KH; Lee SW; Kwon GY; Jang EJ; Kim RK; Choe YJ; Kwon D
    Vaccine; 2024 Mar; 42(7):1440-1444. PubMed ID: 38365479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
    Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
    Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove CA; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jeanes C; Kalra PA; Kyriakidou C; Bradley JM; Munthali C; Minassian AM; McGill F; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Fries L; Cho I; McKnight I; Glenn G; Rivers EJ; Robertson A; Alves K; Smith K; Toback S
    Clin Infect Dis; 2023 Feb; 76(3):398-407. PubMed ID: 36210481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
    Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
    Dunkle LM; Kotloff KL; Gay CL; Áñez G; Adelglass JM; Barrat Hernández AQ; Harper WL; Duncanson DM; McArthur MA; Florescu DF; McClelland RS; Garcia-Fragoso V; Riesenberg RA; Musante DB; Fried DL; Safirstein BE; McKenzie M; Jeanfreau RJ; Kingsley JK; Henderson JA; Lane DC; Ruíz-Palacios GM; Corey L; Neuzil KM; Coombs RW; Greninger AL; Hutter J; Ake JA; Smith K; Woo W; Cho I; Glenn GM; Dubovsky F;
    N Engl J Med; 2022 Feb; 386(6):531-543. PubMed ID: 34910859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
    PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Fix J; Christopher Mast T; Smith K; Baker N
    Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
    Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
    Follmann D; Mateja A; Fay MP; Magaret CA; Huang Y; Fong Y; Angier H; Nason M; Gay CL; Kotloff K; Woo W; Cho I; Dunkle LM
    Clin Infect Dis; 2024 Jul; 79(1):78-85. PubMed ID: 38372392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
    Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove C; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jamal A; Jeanes C; Kalra PA; Kyriakidou C; McAuley DF; Meyrick A; Minassian AM; Minton J; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Albert G; Cho I; Dubovsky F; Glenn G; Rivers J; Robertson A; Smith K; Toback S;
    N Engl J Med; 2021 Sep; 385(13):1172-1183. PubMed ID: 34192426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
    Shinde V; Bhikha S; Hoosain Z; Archary M; Bhorat Q; Fairlie L; Lalloo U; Masilela MSL; Moodley D; Hanley S; Fouche L; Louw C; Tameris M; Singh N; Goga A; Dheda K; Grobbelaar C; Kruger G; Carrim-Ganey N; Baillie V; de Oliveira T; Lombard Koen A; Lombaard JJ; Mngqibisa R; Bhorat AE; Benadé G; Lalloo N; Pitsi A; Vollgraaff PL; Luabeya A; Esmail A; Petrick FG; Oommen-Jose A; Foulkes S; Ahmed K; Thombrayil A; Fries L; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Robertson A; Neal S; Cho I; Glenn GM; Dubovsky F; Madhi SA;
    N Engl J Med; 2021 May; 384(20):1899-1909. PubMed ID: 33951374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
    Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
    J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.